Efficacy of Bleomycin-Lauromacrogol Foam in Pediatric Macrocystic Lymphatic Malformations With and Without Intracapsular Hemorrhage

In brief

This study evaluates whether bleomycin-lauromacrogol foam sclerotherapy achieves comparable treatment outcomes in pediatric macrocystic lymphatic malformations regardless of intralesional hemorrhage status. The research challenges the assumption that hemorrhagic LMs respond less favorably to sclerotherapy than non-hemorrhagic lesions.

• Bleomycin-lauromacrogol foam sclerotherapy shows comparable efficacy in macrocystic lymphatic malformations regardless of intralesional hemorrhage status
• Intracapsular hemorrhage may not be a contraindication to foam sclerotherapy in pediatric macrocystic LMs
• BLF sclerotherapy is a viable treatment option for hemorrhagic macrocystic lymphatic malformations in children

Written by the GCMD Library team from the article.